---
document_datetime: 2026-01-12 12:04:23
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xeljanz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: xeljanz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3147887
conversion_datetime: 2026-01-14 07:16:22.065265
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xeljanz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | B.II.e.7 Change in supplier of packaging | 03/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000315474                     | components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000296333 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from RWE study A3921427 listed as a category 3 study (PASS) in the RMP. This is an observational study of effectiveness and safety of recombinant zoster vaccine (Shingrix) in moderately to severely active ulcerative colitis or rheumatoid arthritis patients treated with tofacitinib (Xeljanz) in real- | 27/11/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Variation type II / EMA/VR/0000296118 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4, and 4.8 of the SmPC in order to add cerebral venous sinus thrombosis (CVST) as a subtype of Venous Thromboembolism to the footnote of the Table 'Adverse Reactions' based on the                                                                                                                    | 27/11/2025 |     | SmPC and PL | Based on an internal safety signal, section 4.4 and 4.8 of the SmPC were updated to add cerebral venous sinus thrombosis (CVST) as a subtype of Venous Thromboembolism to the footnote of the Table 'Adverse Reactions'. The package leaflet has been updated accordingly. For more information, please refer to the Summary of Product Characteristics. SmPC new text As proposed by the MAH: Cerebral venous sinus thrombosis (CVST) has been added as a subtype to the ADR VTE in the footnote of Adverse reactions Table, in Section 4.8 Undesirable effects of the XeljanzÂ® (tofacitinib) |

<div style=\"page-break-after: always\"></div>

|                                          | Applicant's internal safety signal. The package leaflet has been updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                 | SmPC. In addition, the MAH is also adding a cross - reference to Section 4.8 Tablea to the text pertaining to VTE in Section 4.4.                                                                                                                    |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000306831 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                          | 17/10/2025 |     | Annex II and PL |                                                                                                                                                                                                                                                      |
| PSUR / EMA/PSUR/0000248531               | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/06/2025 |     |                 | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing tofacitinib remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |
| Variation type IA / EMA/VR/0000263187    | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate | 03/04/2025 | N/A |                 |                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|